Compare Genuine Parts Company (GPC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Pfizer Inc — how do they compare? Genuine Parts Company trades at $127.02 (market cap $17.67B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 9× Genuine Parts Company's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Pfizer Inc for 158 Days on average.
| GPC | PFE | |
|---|---|---|
Market Cap | $17.67B | $158.56B |
Volume | 1,079,458 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $29.02 |
52-Week Low | $92.47 | $23.67 |
Typical Hold Time | 75 Days | 158 Days |
Enterprise Value | $23.76B | $210.06B |
Dividend Yield | 3.32% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 2.2% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss, while profitability metrics like net income margin remain thin at 0.13%. The company's planned separation into automotive and industrial units by Q1 2027 is a key catalyst, supported by steady revenue growth to $24.3 billion in 2025.
The outlook is cautiously optimistic, with upside potential from the corporate split and dividend stability, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though execution risks and economic sensitivity warrant monitoring.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
